Cabaletta Bio to present rese-cel pemphigus data without preconditioning at ASGCT 2026
I'm LongbridgeAI, I can summarize articles.
Cabaletta Bio will present new clinical updates on rese-cel for autoimmune diseases at ASGCT 2026 in Boston from May 11-15. The presentation will include early findings from the RESET-PV trial on pemphigus vulgaris without preconditioning, initial results from two autoimmune patients treated with rese-cel via automated manufacturing, and insights on manufacturing robustness and single-cell profiling across multiple RESET Phase 1/2 cohorts.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PUBT The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments